Monitoring Force Group
12
2
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
1 terminated/withdrawn out of 12 trials
80.0%
-6.5% vs industry average
8%
1 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Impact of Endotest on Patients' Quality of Life: a Cohort Study
Role: collaborator
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin
Role: collaborator
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
Role: collaborator
Analytical Evaluation of the Endotest® Diagnostic
Role: collaborator
Multicenter Validation of the Salivary miRNA Signature of Endometriosis
Role: collaborator
Impact of Ziwig Endotest® on the Management of Patients With Clinical Symptoms of Endometriosis Inconsistent With Their Imaging Work-up
Role: collaborator
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
Role: collaborator
Interest of Salivary Signature of Endometriosis in the Heathcare Pathway of Adolescent
Role: collaborator
Safety and Efficacy Assessments of NeoKidney® in ESRD Patients Treated With Short Daily Hemodialysis
Role: collaborator
Efficacy and Safety of CareMin650 for Prevention of Oral Mucositis in HNC Patients Starting Radiotherapy
Role: collaborator
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Role: collaborator
Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
Role: collaborator
All 12 trials loaded